Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
interferon-a-2a · 1 trial · 1 indication
Treatment failure was defined as an event of any of the following: progressive disease while receiving study treatment, death due to any cause, or the initiation of another type of treatment due to stable disease, progressive disease or relapse, or intolerance to study treatment.
The median time, in months, between randomization and treatment failure event determined using Kaplan-Meier estimates.
| Arm | Type | Description |
|---|---|---|
| Rituximab Monotherapy | ACTIVE_COMPARATOR | Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment. |
| Rituximab, Interferon | EXPERIMENTAL | Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment. |
| Name | Type | Description |
|---|---|---|
| rituximab | DRUG | 375 mg/m2 rituximab i.v. weekly for 4 weeks |
| interferon-a-2a | DRUG | 3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5 |
Inclusion Criteria: * Adult patients \>18 years of age * CD20+ low-grade (indolent) lymphoma of follicular and marginal zone type, small lymphocytic lymphoma without a B-CLL phenotype, or indolent lymphoma not otherwise specified * Stage II (with bulky disease), III, or IV lymphoma * No previous ch...
Top 20 of 66 competitors
Interferon-a-2a is used for the treatment of lymphoma, specifically in patients with follicular or other CD20+ low-grade (indolent) lymphoma. It is being studied in combination with rituximab (MabThera/Rituxan) in a Phase 3 clinical trial. The drug is administered to adult patients aged 18 years and older.
Interferon-a-2a is a small molecule that targets the immune system to fight cancer cells. It works by modulating the body's immune response, helping to slow or stop the growth of lymphoma cells. The drug is being evaluated in combination with rituximab, which targets the CD20 protein on B-cells, for the treatment of low-grade lymphoma.
Interferon-a-2a is developed by Roche Holding AG, a multinational healthcare company. The company's stock is traded under the ticker symbol RHHBY. Roche is conducting clinical trials to evaluate the drug's efficacy in treating lymphoma, particularly in combination with rituximab.
Interferon-a-2a is in Phase 3 clinical development for the treatment of lymphoma. The drug is currently being studied in a Phase 3 trial that has been completed. It is an investigational drug and has not yet been approved for this indication. The trial enrolled 313 patients with follicular or other CD20+ low-grade lymphoma.
Interferon-a-2a is being studied in clinical trial NCT01609010, a Phase 3 study titled 'A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma.' The trial was conducted in Denmark, Norway, and Sweden, enrolled 313 patients, and has been completed.
Yes, interferon-a-2a is also known as Roferon-A. In the clinical trial NCT01609010, the drug is referred to as Roferon-A, which is the brand name for interferon-a-2a. The trial evaluates the combination of Roferon-A with rituximab for the treatment of follicular or other CD20+ low-grade lymphoma.